Brief: NextCure Provides Update On Phase 2 Study Of Anti-Siglec-15 Antibody NC318

NextCure

12/09/2023 14:25

Sept 12 (Reuters) - NextCure Inc  NXTC.O :
    * A PHASE 2 STUDY OF ANTI-SIGLEC-15 ANTIBODY, NC318, IN
COMBINATION WITH PEMBROLIZUMAB (NCT04699123) DEMONSTRATES
CLINICAL ACTIVITY IN PATIENTS WITH ADVANCED PD-1 AXIS INHIBITOR
REFRACTORY NSCLC
    * NEXTCURE INC: EFFICACY DATA DEMONSTRATE THAT COMBINATION
OF
NC318 AND PEMBROLIZUMAB IS ACTIVE IN ADVANCED PD-1 AXIS
INHIBITOR REFRACTORY NSCLC
    * NEXTCURE INC: TO DATE, BOTH MONOTHERAPY AND COMBINATION
ARMS
HAVE BEEN WELL TOLERATED

Source text for Eikon:  ID:nGNX4rjgPp 
Further company coverage:  NXTC.O 

 ((reuters.briefs@thomsonreuters.com;))